Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,227 recruiting studies in this area right now.
By phase
- Not applicable3,140
- Phase 21,067
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4236
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis342
- Multiple Myeloma333
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes132
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona140
- New York122
- Massachusetts119
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,227 total
- NCT07746427Recruiting
Mindfulness meditation for teens with eczema
This study tests whether a smartphone-based mindfulness meditation program can help teenagers with moderate to severe eczema (atopic dermatitis) that hasn't improved with standard creams. Participants will learn relaxation techniques to possibly reduce itching and skin inflammation.
New York, New YorkAges 12–17 - NCT06660355RecruitingPhase 2
Comparing two medicines for chronic graft-versus-host disease
This trial compares two treatments, ruxolitinib and prednisone, as the first therapy for chronic graft-versus-host disease (cGVHD), a condition where donor cells attack your body after a stem cell transplant. The goal is to see which medicine works better and has fewer side effects.
Miami, FloridaAges 18 years+ - NCT07748169Recruiting
Observational study of skin disease patients
This study looks at the health records of people with skin diseases to learn more about their care and outcomes. It may help improve future treatments.
Winston-Salem, North CarolinaAges Any age - NCT07371403Recruiting
Car-t cell therapy for relapsed or refractory acute lymphoblastic leukemia
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
AmmanAges 1 year+ - NCT06506643RecruitingPhase 1/Phase 2
Study of KLS-1 for solid tumors and CLL
This trial tests a new drug called KLS-1 for people with solid tumors (like melanoma, pancreatic, or prostate cancer) or chronic lymphocytic leukemia (CLL) that is no longer responding to standard treatments. The goal is to see if KLS-1 is safe and can shrink tumors or slow the cancer.
KropyvnytskyiAges 18 years+ - NCT06124157RecruitingPhase 2
Targeted therapy plus chemo for children with Ph+ or Ph-like B-ALL
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
Birmingham, AlabamaAges 1 year–46 years - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Anchorage, AlaskaAges 40–75 - NCT07321652RecruitingPhase 3
Sonrotoclax plus zanubrutinib for untreated CLL or SLL
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
Los Angeles, CaliforniaAges 65 years+ - NCT07228962Recruiting
Skin clues for eczema in babies
This study looks at tiny skin samples from babies to find clues about eczema. It uses a gentle, painless device that sucks up a small piece of skin. If your baby has eczema or is healthy and under 6 months old, you may be able to join.
LondonAges birth–6 months - NCT05435547RecruitingPhase 4
Pre-surgery steroid medicine for autoimmune thyroid disease
This trial tests whether taking corticosteroids (anti-inflammatory medicines) before thyroid surgery is safe and helpful for people with autoimmune thyroid disease. It focuses on Graves’ or Hashimoto’s disease patients who are planning total thyroid removal.
Indianapolis, IndianaAges 18 years+ - NCT06084936RecruitingPhase 3
Glofitamab alone vs other treatments for mantle cell lymphoma
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
Berkeley, CaliforniaAges 18 years+ - NCT07298447RecruitingPhase 3
Donidalorsen for children with hereditary angioedema
This study tests a new medicine, donidalorsen, to prevent swelling attacks in children ages 2 to 11 with hereditary angioedema (HAE). If your child has HAE type 1 or 2, this trial may help find a treatment option.
Santa Monica, CaliforniaAges 2–11 - NCT07587125RecruitingPhase 1
CAR-T Cell Therapy for Progressive Multiple Sclerosis
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
Xi'an, ShaanxiAges 18–75 - NCT07673367RecruitingPhase 2
Nemtabrutinib with CAR T for relapsed mantle cell lymphoma
This trial tests adding a targeted pill (nemtabrutinib) to standard CAR T-cell therapy for people with mantle cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination works better than CAR T alone.
Nashville, TennesseeAges 18 years+ - NCT05039619RecruitingPhase 2
Obinutuzumab trial for adolescents with active lupus kidney inflammation
This Phase 2 study tests obinutuzumab, a targeted antibody medicine, in teens with active lupus nephritis (inflammation in the kidney). It looks at whether it helps kidney disease and is safe, including how the body handles the drug.
Loma Linda, CaliforniaAges 5–17 - NCT07614477RecruitingPhase 2
Testing EVER001 for kidney protein-loss diseases
This study tests a new drug called EVER001 to see if it can reduce protein loss in urine and improve kidney function in patients with specific kidney diseases (FSGS, MCD, or IgAN). These are autoimmune kidney conditions that cause the kidneys to leak protein into the urine.
Beijing, Beijing MunicipalityAges 18–75 - NCT06197685Recruiting
Combining treatments to improve memory in multiple sclerosis
This trial tests a combination of two approaches to help people with MS improve memory and learning. If you have mild-to-moderate mobility issues and are not very active, you may be able to join.
East Hanover, New JerseyAges 18–70 - NCT02872987Recruiting
Adult blood cancer registry study with stored samples
This study enrolls adults with certain blood cancers to better understand diagnosis, treatment choices, and outcomes. You may also be asked to provide or have tissue/blood samples saved so researchers can study what’s going on in the disease.
GrazAges 18 years+ - NCT07255157Recruiting
Peripheral Helper T-cells in CVID
This study looks at a specific type of immune cell in people with Common Variable Immune Deficiency (CVID). It aims to learn more about how these cells behave and may help guide better treatments for this condition.
PessacAges 18 years+ - NCT07293403RecruitingPhase 2
Duvelisib maintenance for peripheral T-cell lymphoma
This trial tests whether the drug duvelisib can help keep T-cell lymphoma in remission after initial chemotherapy. It is for people who have finished first-line treatment with a CHOP-like regimen, achieved a complete response, and cannot or choose not to have a stem cell transplant.
Duarte, CaliforniaAges 18 years+ - NCT06675123RecruitingPhase 1
Pacritinib with a BTK inhibitor for mantle cell lymphoma
This trial tests a new combination of two targeted drugs (pacritinib plus a BTK inhibitor like ibrutinib) for people with mantle cell lymphoma that has come back or stopped responding to treatment. It may help if your current BTK inhibitor is no longer working well.
Duarte, CaliforniaAges 18 years+ - NCT06232044RecruitingPhase 1/Phase 2
Testing a new drug combo for returning multiple myeloma
This trial tests a combination of two approved drugs (lenalidomide and dexamethasone) plus an experimental drug (iberdomide) for people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this new combination can help control the disease.
Ames, IowaAges 18 years+ - NCT06895538RecruitingPhase 2/Phase 3
Comparing two immune treatments for stem cell transplant patients
This trial compares two drugs, ATLG and ATG, to see which one helps rebuild the immune system better after a stem cell transplant for blood cancer. It aims to improve recovery and reduce complications.
BeijingAges 18 years+ - NCT07215910RecruitingPhase 3
Testing vorasidenib with temozolomide after radiation for advanced brain cancer
This trial tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of advanced brain cancer called IDH-mutant astrocytoma. It is for patients who have not had previous treatments like chemotherapy or radiation and whose tumors have certain genetic features.
Duarte, CaliforniaAges 12 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,227 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,696 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.